Rhythm Pharmaceuticals, Inc.
RYTM
주식 순위
#3015
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
주가
$90.54
시가총액
$6.23B
변동 (1일)
2.62%
변동 (1년)
-19.44%
국가
US
거래 Rhythm Pharmaceuticals, Inc. (RYTM)
카테고리
Healthcare
Rhythm Pharmaceuticals, Inc. (RYTM)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 27.37
Rhythm Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 27.37입니다. 2023년 말 기준 P/B 비율은 15.62였습니다.
Rhythm Pharmaceuticals, Inc.의 P/B 비율 기록 (2012 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 27.37 | 31.91% |
| 2024 | 20.75 | 32.87% |
| 2023 | 15.62 | 171.92% |
| 2022 | 5.74 | 229.68% |
| 2021 | 1.74 | -77.89% |
| 2020 | 7.88 | 164.74% |
| 2019 | 2.98 | -12.07% |
| 2018 | 3.38 | -36.92% |
| 2017 | 5.36 | -92.20% |
| 2016 | 68.78 | 619.55% |
| 2015 | 9.56 | -101.12% |
| 2014 | -854.44 | 3,155.60% |
| 2013 | -26.25 | -36.85% |
| 2012 | -41.56 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -77.16% |
US
|
|
| 13.2547 | -51.57% |
US
|
|
| 4.208 | -84.63% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.41% |
NL
|
